MDGL Annual CFO
-$324.23 M
-$99.37 M-44.19%
31 December 2023
Summary:
As of January 23, 2025, MDGL annual cash flow from operations is -$324.23 million, with the most recent change of -$99.37 million (-44.19%) on December 31, 2023. During the last 3 years, it has fallen by -$166.67 million (-105.78%). MDGL annual CFO is now -1291.06% below its all-time high of $27.22 million, reached on December 31, 2007.MDGL Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MDGL Quarterly CFO
-$66.98 M
+$67.96 M+50.36%
30 September 2024
Summary:
As of January 23, 2025, MDGL quarterly cash flow from operations is -$66.98 million, with the most recent change of +$67.96 million (+50.36%) on September 30, 2024. Over the past year, it has increased by +$67.96 million (+50.36%). MDGL quarterly CFO is now -197.97% below its all-time high of $68.37 million, reached on December 31, 2007.MDGL Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MDGL TTM CFO
-$431.02 M
+$17.94 M+4.00%
30 September 2024
Summary:
As of January 23, 2025, MDGL TTM cash flow from operations is -$431.02 million, with the most recent change of +$17.94 million (+4.00%) on September 30, 2024. Over the past year, it has increased by +$17.94 million (+4.00%). MDGL TTM CFO is now -1523.53% below its all-time high of $30.28 million, reached on June 30, 2016.MDGL TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MDGL Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -44.2% | +50.4% | +4.0% |
| 3 y3 years | -105.8% | +50.4% | +4.0% |
| 5 y5 years | -1171.1% | +50.4% | +4.0% |
MDGL Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -76.3% | at low | -39.4% | +55.1% | -134.4% | +4.0% |
| 5 y | 5-year | -679.0% | at low | -445.4% | +55.1% | -935.5% | +4.0% |
| alltime | all time | -1291.1% | at low | -198.0% | +55.1% | -1523.5% | +4.0% |
Madrigal Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$66.98 M(-50.4%) | -$431.02 M(-4.0%) |
| June 2024 | - | -$134.94 M(-9.5%) | -$448.95 M(+15.3%) |
| Mar 2024 | - | -$149.16 M(+86.6%) | -$389.32 M(+20.1%) |
| Dec 2023 | -$324.23 M(+44.2%) | -$79.93 M(-5.9%) | -$324.23 M(+7.1%) |
| Sept 2023 | - | -$84.92 M(+12.8%) | -$302.81 M(+9.3%) |
| June 2023 | - | -$75.31 M(-10.4%) | -$276.96 M(+6.9%) |
| Mar 2023 | - | -$84.07 M(+43.7%) | -$259.01 M(+15.2%) |
| Dec 2022 | -$224.86 M(+22.3%) | -$58.52 M(-0.9%) | -$224.86 M(+4.9%) |
| Sept 2022 | - | -$59.07 M(+3.0%) | -$214.39 M(+6.7%) |
| June 2022 | - | -$57.36 M(+14.9%) | -$200.88 M(+5.5%) |
| Mar 2022 | - | -$49.91 M(+3.9%) | -$190.40 M(+3.5%) |
| Dec 2021 | -$183.92 M(+16.7%) | -$48.05 M(+5.5%) | -$183.92 M(-3.6%) |
| Sept 2021 | - | -$45.56 M(-2.8%) | -$190.81 M(-1.2%) |
| June 2021 | - | -$46.88 M(+7.9%) | -$193.11 M(+13.3%) |
| Mar 2021 | - | -$43.43 M(-21.0%) | -$170.48 M(+8.2%) |
| Dec 2020 | -$157.56 M(+278.5%) | -$54.95 M(+14.8%) | -$157.56 M(+37.1%) |
| Sept 2020 | - | -$47.85 M(+97.3%) | -$114.90 M(+46.6%) |
| June 2020 | - | -$24.26 M(-20.5%) | -$78.37 M(+19.4%) |
| Mar 2020 | - | -$30.51 M(+148.4%) | -$65.65 M(+57.7%) |
| Dec 2019 | -$41.62 M(+63.2%) | -$12.28 M(+8.5%) | -$41.62 M(+16.9%) |
| Sept 2019 | - | -$11.32 M(-1.9%) | -$35.61 M(+20.6%) |
| June 2019 | - | -$11.54 M(+78.1%) | -$29.52 M(+26.5%) |
| Mar 2019 | - | -$6.48 M(+3.4%) | -$23.34 M(-8.5%) |
| Dec 2018 | -$25.51 M(+14.3%) | -$6.26 M(+19.6%) | -$25.51 M(+1.3%) |
| Sept 2018 | - | -$5.24 M(-2.3%) | -$25.19 M(+1.2%) |
| June 2018 | - | -$5.36 M(-38.0%) | -$24.90 M(-8.4%) |
| Mar 2018 | - | -$8.64 M(+45.4%) | -$27.19 M(+21.8%) |
| Dec 2017 | -$22.32 M(+26.7%) | -$5.95 M(+20.1%) | -$22.32 M(+3.1%) |
| Sept 2017 | - | -$4.95 M(-35.3%) | -$21.65 M(-16.5%) |
| June 2017 | - | -$7.65 M(+102.9%) | -$25.94 M(+23.9%) |
| Mar 2017 | - | -$3.77 M(-28.6%) | -$20.94 M(+18.9%) |
| Dec 2016 | -$17.61 M(+460.4%) | -$5.28 M(-42.9%) | -$17.61 M(+31.2%) |
| Sept 2016 | - | -$9.24 M(+249.2%) | -$13.42 M(-144.3%) |
| June 2016 | - | -$2.65 M(+504.3%) | $30.28 M(+99.3%) |
| Mar 2016 | - | -$438.00 K(-60.0%) | $15.20 M(-583.6%) |
| Dec 2015 | -$3.14 M | -$1.10 M(-103.2%) | -$3.14 M(-85.2%) |
| Sept 2015 | - | $34.46 M(-294.4%) | -$21.26 M(-71.4%) |
| June 2015 | - | -$17.73 M(-5.6%) | -$74.29 M(-4.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | -$18.77 M(-2.3%) | -$77.43 M(-1.9%) |
| Dec 2014 | -$78.92 M(+2.0%) | -$19.21 M(+3.5%) | -$78.92 M(+0.7%) |
| Sept 2014 | - | -$18.57 M(-11.1%) | -$78.40 M(+2.6%) |
| June 2014 | - | -$20.87 M(+3.0%) | -$76.42 M(+1.3%) |
| Mar 2014 | - | -$20.27 M(+8.5%) | -$75.47 M(-2.5%) |
| Dec 2013 | -$77.41 M(+43.0%) | -$18.69 M(+12.7%) | -$77.41 M(+8.7%) |
| Sept 2013 | - | -$16.59 M(-16.7%) | -$71.24 M(+4.9%) |
| June 2013 | - | -$19.92 M(-10.3%) | -$67.92 M(+11.2%) |
| Mar 2013 | - | -$22.21 M(+77.4%) | -$61.09 M(+12.9%) |
| Dec 2012 | -$54.13 M(+14.5%) | -$12.52 M(-5.6%) | -$54.13 M(+3.9%) |
| Sept 2012 | - | -$13.26 M(+1.3%) | -$52.10 M(+2.8%) |
| June 2012 | - | -$13.10 M(-14.2%) | -$50.66 M(+1.9%) |
| Mar 2012 | - | -$15.25 M(+45.5%) | -$49.72 M(+5.1%) |
| Dec 2011 | -$47.30 M(+23.8%) | -$10.49 M(-11.3%) | -$47.30 M(+5.1%) |
| Sept 2011 | - | -$11.82 M(-2.7%) | -$45.03 M(+8.2%) |
| June 2011 | - | -$12.15 M(-5.3%) | -$41.63 M(+8.3%) |
| Mar 2011 | - | -$12.84 M(+56.3%) | -$38.45 M(+0.7%) |
| Dec 2010 | -$38.20 M(+42.5%) | -$8.21 M(-2.5%) | -$38.20 M(+2.5%) |
| Sept 2010 | - | -$8.43 M(-6.1%) | -$37.25 M(+0.5%) |
| June 2010 | - | -$8.97 M(-28.7%) | -$37.08 M(-28.2%) |
| Mar 2010 | - | -$12.59 M(+73.3%) | -$51.63 M(+92.6%) |
| Dec 2009 | -$26.81 M(-29.3%) | -$7.26 M(-11.9%) | -$26.81 M(+795.8%) |
| Sept 2009 | - | -$8.25 M(-64.9%) | -$2.99 M(-79.5%) |
| June 2009 | - | -$23.52 M(-292.4%) | -$14.57 M(+45.8%) |
| Mar 2009 | - | $12.23 M(-26.1%) | -$9.99 M(-73.7%) |
| Dec 2008 | -$37.94 M(-239.4%) | $16.55 M(-183.5%) | -$37.94 M(-373.3%) |
| Sept 2008 | - | -$19.83 M(+4.7%) | $13.88 M(-24.2%) |
| June 2008 | - | -$18.94 M(+20.5%) | $18.31 M(-25.8%) |
| Mar 2008 | - | -$15.72 M(-123.0%) | $24.68 M(-9.3%) |
| Dec 2007 | $27.22 M(-151.4%) | $68.37 M(-543.8%) | $27.22 M(-166.2%) |
| Sept 2007 | - | -$15.41 M(+22.6%) | -$41.15 M(+59.8%) |
| June 2007 | - | -$12.57 M(-4.6%) | -$25.75 M(+95.4%) |
| Mar 2007 | - | -$13.18 M(-1.4%) | -$13.18 M(-1.4%) |
| Dec 2006 | -$52.98 M(-14.4%) | - | - |
| Dec 2005 | -$61.88 M(+83.1%) | - | - |
| Mar 2005 | - | -$13.37 M | -$13.37 M |
| Dec 2004 | -$33.80 M(+43.1%) | - | - |
| Dec 2003 | -$23.61 M | - | - |
FAQ
- What is Madrigal Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual CFO year-on-year change?
- What is Madrigal Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly CFO year-on-year change?
- What is Madrigal Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals TTM CFO year-on-year change?
What is Madrigal Pharmaceuticals annual cash flow from operations?
The current annual CFO of MDGL is -$324.23 M
What is the all time high annual CFO for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual cash flow from operations is $27.22 M
What is Madrigal Pharmaceuticals annual CFO year-on-year change?
Over the past year, MDGL annual cash flow from operations has changed by -$99.37 M (-44.19%)
What is Madrigal Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of MDGL is -$66.98 M
What is the all time high quarterly CFO for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly cash flow from operations is $68.37 M
What is Madrigal Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, MDGL quarterly cash flow from operations has changed by +$67.96 M (+50.36%)
What is Madrigal Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of MDGL is -$431.02 M
What is the all time high TTM CFO for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high TTM cash flow from operations is $30.28 M
What is Madrigal Pharmaceuticals TTM CFO year-on-year change?
Over the past year, MDGL TTM cash flow from operations has changed by +$17.94 M (+4.00%)